Introduction: High on-treatment platelet reactivity (HTPR) on clopidogrel correlates with adverse clinical outcomes in patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI) 1 . Whether HTPR on clopidogrel is a modifiable risk factor for ischemic events is not clear. We sought to evaluate the effect of the serial clopidogrel dose tailoring after platelet function testing (PFT) on a clinical outcome of the patients with determined HTPR after successful PCI in ACS.
Patients and Methods:
We screened 461 consecutive ACS patients. Exclusion criteria was present in 120 patients (continuous postinterventional glycoprotein (GP) IIbIIIa receptor inhibitor perfusion, thrombocytopenia (<150x109/L), significant renal insufficiency (creatinine>200 µmol/L), anemia (Htc<30%), hemorrhagic diathesis, concomitant chronic anticoagulation therapy and advanced age (>80 years of age). Patients without exclusion criteria (341) LD -loading dose; MEA -Multiplate elecrode aggregometry; MD -maintenance dose clopidogrel (n=87; 25.5%) were included in the study and randomized to the standard dose clopidogrel (control) group (n=44) and the interventional group (n=43). Blood samples for PFT using Multiplate ® function analyzer (MEA) were drawn at day 1, 2, 3, 7, 30 and at month 2, 3, 6, 9 and 12 following PCI. The clopidogrel dose was modified at each PFT the interventional group with patients taking up to three 600 mg loading doses and a range of 75-300 mg maintenance dose of clopidogrel to achieve an optimal platelet reactivity (19-46 U) as set by the consensus statement 2 .
Results: Nine (20.9%) and 18 (41.8%) patients experienced either ischemic or bleeding adverse event in the interventional and control group during the 12-month follow up, respectively (p = 0.044). Composite ischemic events (hospitalization due to ischemia, target vessel revascularization, non-fatal myocardial infarction, stent thrombosis, stroke, cardiovascular death) were also significantly higher in the control group (16 vs 7 patients; p = 0.034). There was no difference in total bleeding outcomes (p=1.000).
Conclusion:
We hypothesize that HTPR to clopidogrel is a modifiable risk factor and personalized antiplatelet therapy based on PFT might be implemented in ACS patients treated with PCI. Larger, similarly designed randomized studies are needed to confirm these results.
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